Free Trial

ICON Public (ICLR) Stock Forecast & Price Target

$220.47
-1.26 (-0.57%)
(As of 10/25/2024 ET)

ICON Public - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
3
Buy
11

Based on 14 Wall Street analysts who have issued ratings for ICON Public in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 3 have given a hold rating, 10 have given a buy rating, and 1 has given a strong buy rating for ICLR.

Consensus Price Target

$310.45
40.81% Upside
According to the 14 analysts' twelve-month price targets for ICON Public, the average price target is $310.45. The highest price target for ICLR is $363.00, while the lowest price target for ICLR is $270.00. The average price target represents a forecasted upside of 40.81% from the current price of $220.47.
Get the Latest News and Ratings for ICLR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ICON Public and its competitors.

Sign Up

ICLR Analyst Ratings Over Time

TypeCurrent Forecast
10/28/23 to 10/27/24
1 Month Ago
9/28/23 to 9/27/24
3 Months Ago
7/30/23 to 7/29/24
1 Year Ago
10/28/22 to 10/28/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
10 Buy rating(s)
10 Buy rating(s)
10 Buy rating(s)
10 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$310.45$310.45$310.45$310.45
Forecasted Upside40.81% Upside40.81% Upside40.81% Upside40.81% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

ICLR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ICLR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ICON Public Stock vs. The Competition

TypeICON PublicMedical CompaniesS&P 500
Consensus Rating Score
2.86
2.79
2.50
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside40.81% Upside7,918.34% Upside9.13% Upside
News Sentiment Rating
Neutral News

See Recent ICLR News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/25/2024TD Cowen
4 of 5 stars
 Lower TargetBuy ➝ Buy$369.00 ➝ $285.00+28.55%
10/25/2024Barclays
3 of 5 stars
 Lower TargetOverweight ➝ Overweight$330.00 ➝ $275.00+24.47%
10/25/2024JPMorgan Chase & Co.
3 of 5 stars
 Lower TargetOverweight ➝ Overweight$375.00 ➝ $280.00+22.95%
10/25/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$370.00 ➝ $280.00+22.95%
10/25/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$376.00 ➝ $270.00+20.64%
10/24/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Coldwell
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
10/24/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral$340.00 ➝ $340.00+21.10%
10/14/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$383.00 ➝ $363.00+22.84%
10/14/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Clark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$311.00+5.43%
10/8/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$360.00 ➝ $350.00+21.46%
9/18/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/31/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
4/4/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$346.00+7.76%
12/11/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$300.00 ➝ $315.00+15.61%
7/14/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$280.00 ➝ $300.00+21.55%
5/1/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$245.00 ➝ $220.00+14.17%
4/28/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$271.00 ➝ $263.00+37.91%
11/9/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$265.00 ➝ $260.00+33.29%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 08:28 AM ET.


Should I Buy ICON Public Stock? ICLR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, October 20, 2024. Please send any questions or comments about these ICON Public pros and cons to contact@marketbeat.com.

ICON Public
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in ICON Public Limited:

  • ICON Public Limited has a strong financial position with a debt-to-equity ratio of 0.36, indicating a healthy balance between debt and equity which can provide stability and growth opportunities.
  • The company's quick ratio and current ratio of 1.31 each suggest that ICON Public Limited has sufficient liquid assets to cover its short-term liabilities, reflecting good financial health.
  • Recent earnings results have been positive, with the company reporting $3.75 earnings per share for the quarter, surpassing analysts' estimates. This demonstrates strong financial performance and potential for growth.
  • Analysts have issued favorable ratings for ICON Public Limited, with a consensus of "Buy" and an average target price of $351.60, indicating confidence in the company's future prospects.
  • Despite a recent 2.2% trading dip, ICON Public Limited's stock price of $296.30 presents a potential buying opportunity for investors looking to enter at a lower price point.

ICON Public
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in ICON Public Limited for these reasons:

  • While the company has shown positive earnings, there is a slight revenue decrease of 4.1% on a year-over-year basis, which may indicate a potential challenge in maintaining revenue growth.

ICLR Forecast - Frequently Asked Questions

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for ICON Public is $310.45, with a high forecast of $363.00 and a low forecast of $270.00.

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ICON Public in the last twelve months. There are currently 3 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ICLR shares.

According to analysts, ICON Public's stock has a predicted upside of 40.81% based on their 12-month stock forecasts.

Over the previous 90 days, ICON Public's stock had 2 downgrades and 1 upgrade by analysts.

Analysts like ICON Public more than other "medical" companies. The consensus rating score for ICON Public is 2.86 while the average consensus rating score for "medical" companies is 2.79. Learn more on how ICLR compares to other companies.


This page (NASDAQ:ICLR) was last updated on 10/27/2024 by MarketBeat.com Staff
From Our Partners